Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VINDIP
- Development stage
- Phase 4
- Lead developer
- VINS Bio Products
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
VINDIP is an equine-derived diphtheria antitoxin developed and marketed by Vins Bioproducts Limited. It is a polyclonal immunoglobulin biologic prepared by hyperimmunizing horses with diphtheria toxin or toxoid. The resulting plasma is enzymatically refined, purified, and concentrated to produce antibodies that specifically neutralize the toxin secreted by Corynebacterium diphtheriae, the causative agent of diphtheria. Administered via intramuscular injection, VINDIP provides immediate passive immunity by neutralizing circulating toxin before it can bind to host tissues. It has been marketed in India since 2006 and is typically supplied as a 10,000 I.U. solution in 10 mL vials.
- Brand names
- VINDIP
- Other names
- Diphtheria Antitoxin I.P.Diphtheria Antitoxin B.P.Diphtheria Antitoxin (Equine)
02
Targets
Beyond the preview
Go deeper on VINDIP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VINDIP.